

10030877, 042202

JC10 Rec'd PCT/PTO 19 OCT 2001

Form PTO 1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 5-93)		ATTORNEY'S DOCKET NUMBER P32293
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>10/030877</b>
INTERNATIONAL APPLICATION NO. PCT/GB00/01522	INTERNATIONAL FILING DATE 19 April 2000	PRIORITY DATE CLAIMED 23 April 1999
TITLE OF INVENTION NOVEL PHARMACEUTICAL		
APPLICANT(S) FOR DO/EO/US Paul David James BLACKLER, Robert Gordon GILES, Stephen MOORE and Michael John SASSE		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. to 16. below concern other document(s) or information included:**

11. ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☒ Please amend the specification by inserting before the first line the sentence: This is a 371 of International Application PCT/GB00/01522, filed 19 April 2000.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ An Abstract on a separate sheet of paper;
19. ☐ Other items or information:


537 REC'D PCT 19 OCT 2001

US APPLICATION NO. <b>10/030877</b>		INTERNATIONAL APPLICATION NO. PCT/GB00/01522		ATTORNEYS DOCKET NO P32293	
20. [X] The following fees are submitted:				CALCULATIONS PTO USE ONLY	
<b>Basic National Fee (37 C.F.R. 1.492(a)(1)-(5)):</b>				<b>\$890.00</b>	
Search Report has been prepared by the EPO or JPO ..... <b>\$890.00</b>					
International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) ..... <b>\$710.00</b>					
No International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... <b>\$740.00</b>					
Neither International Preliminary Examination Fee (37 CFR 1.492) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... <b>\$1,040.00</b>					
International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) and all claims satisfied provisions of PCT Article 33(2)-(4)..... <b>\$100.00</b>					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$890.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<b>\$0.00</b>	
Claims	Number Filed	Number Extra	Rate		
Total claims	<b>11 - 20 =</b>	<b>0</b>	<b>0 x \$18.00</b>	<b>\$0.00</b>	
Independent claims	<b>1 - 3 =</b>	<b>0</b>	<b>0 x \$84.00</b>	<b>\$0.00</b>	
Multiple dependent claims (if applicable)			<b>+ \$280.00</b>	<b>\$0.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$</b>	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				<b>\$</b>	
<b>SUBTOTAL =</b>				<b>\$</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)) +				<b>\$</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$890.00</b>	
				Amount to be refunded	\$
				charged	\$

- a. ☐ A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 19-2570 in the amount of **\$890.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570. A duplicate copy of this sheet is enclosed.
- d. ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application (37 CFR 1.136 (a)(3)).

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:  
GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5018  
Facsimile (610) 270-5073

  
SIGNATURE  
**Yuriy P. Stercho, Ph.D.**  
NAME  
33,797  
REGISTRATION NO.

10030877/042203  
10/030877

531 Rec'd PCT/F 19 OCT 2001

**"EXPRESS MAIL CERTIFICATE"**  
**"EXPRESS MAIL" MAILING LABEL NUMBER EV000521205US**  
**DATE OF DEPOSIT 19 OCTOBER 2001**

Attorney Docket No. P32293

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB00/01522	19 April 2000	23 April 1999

TITLE OF INVENTION  
NOVEL PHARMACEUTICAL

APPLICANT(S) FOR DO/US

Paul David James BLACKLER, Robert Gordon GILES, Stephen MOORE and Michael John SASSE

**PRELIMINARY AMENDMENT**

Preliminary to the examination of this application, Applicants respectfully request amendment of the above-identified application as follows:

**In the Specification:**

Kindly add the Abstract enclosed herewith on a separate sheet, at the end.

**In the Claims:**

Please cancel claims 11-13.

Please amend claims 1, 3-8, and 14 as follows:

1. (Amended) A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the Polymorph) comprising:

- (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602  $\text{cm}^{-1}$ ; and/or
- (ii) a Raman spectrum containing peaks at 1751, 1243 and 602  $\text{cm}^{-1}$ ; and/or
- (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 170.7, 172.0 and 175.0 ppm; and/or
- (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms.

3. (Amended) A Polymorph according to claim 1, which provides a Raman spectrum substantially in accordance with Figure II.

4. (Amended) A Polymorph according to claim 1, which provides a solid-state nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I.

Int'l App. No.: PCT/GB00/01522

Int'l Filing Date: 19 April 2000

5. (Amended) A Polymorph according to claim 1, which provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or Table II.
6. (Amended) A Polymorph according to claim 1, in isolated form.
7. (Amended) A Polymorph according to claim 1, in pure form.
8. (Amended) A Polymorph according to claim 1, in crysalline form.
14. (Amended) A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Polymorph according to claim 1 to a human or non-human mammal in need thereof.

#### **REMARKS**

The above-identified application is being entered into the National Phase from PCT application No. PCT/GB00/01522.

Applicants have amended the claims to put them in conformity with U.S. practice. Attached hereto is a marked up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

No new matter has been introduced.

Respectfully submitted,



**Yuriy P. Stercho, Ph.D.**  
Attorney for Applicants  
Registration No. 33,797

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5018  
Facsimile (610) 270-5073  
n\yps\response\P32293\preamd.

Int'l App. No.: PCT/GB00/01522  
Int'l Filing Date: 19 April 2000

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

An abstract has been added.

**In the Claims:**

Claims 11-13 have been canceled.

1. (Amended) A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the Polymorph) [characterized in that it provides:] comprising:
  - (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602  $\text{cm}^{-1}$ ; and/or
  - (ii) a Raman spectrum containing peaks at 1751, 1243 and 602  $\text{cm}^{-1}$ ; and/or
  - (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 170.7, 172.0 and 175.0 ppm; and/or
  - (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms.
3. (Amended) A Polymorph according to claim 1 [or claim 2], which provides a Raman spectrum substantially in accordance with Figure II.
4. (Amended) A Polymorph according to [any one of] claim[s] 1 [to 3], which provides a solid-state nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I.
5. (Amended) A Polymorph according to [any one of] claim[s] 1 [to 4], which provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or Table II.
6. (Amended) A Polymorph according to [any one of] claim[s] 1 [to 5], in isolated form.
7. (Amended) A Polymorph according to [any one of] claim[s] 1 [to 6], in pure form.
8. (Amended) A Polymorph according to [any one of] claim[s] 1 [to 7], in crystalline form.

Int'l App. No.: PCT/GB00/01522  
Int'l Filing Date: 19 April 2000

14. (Amended) A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Polymorph according to claim 1 to a human or non-human mammal in need thereof.

10030277/1030802

Rec'd PCT/PTO 22 APR 2002

**"EXPRESS MAIL CERTIFICATE"**  
**"EXPRESS MAIL" MAILING LABEL NUMBER EV000522885US**  
**DATE OF DEPOSIT 22 April 2002**

Attorney Docket No. P32293

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB00/01522	19 April 2000	23 April 1999

TITLE OF INVENTION  
NOVEL PHARMACEUTICAL

APPLICANT(S) FOR DO/US

Paul David James BLACKLER, Robert Gordon GILES, Stephen MOORE and Michael John SASSE

**SUPPLEMENTARY PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.111**

Preliminary to the examination of this application, Applicants respectfully request amendment of the above-identified application as follows:

**In the Title:**


Please amend the title to read:

-- THIAZOLIDINEDIONE DERIVATIVE AND ITS USE AS ANTIDIABETIC --

**REMARKS**

For clarification, the title has been amended. No new matter has been added.  
Attached hereto is a marked up version of the change made to the title by the current amendment. The attached page is captioned "**Version with Markings to Show Changes Made.**"

Respectfully submitted,

  
**Yuriy P. Stercho, Ph.D.**  
Attorney for Applicants  
Registration No. 33,797

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5018  
Facsimile (610) 270-5073  
n:\yps\response\P32293\preamd02.

Int'l App. No.: PCT/GB00/01522  
Int'l Filing Date: 19 April 2000

**Version with Markings to Show Changes Made**

**In the Title:**

[NOVEL PHARMACEUTICAL] THIAZOLIDINEDIONE DERIVATIVE AND ITS USE AS  
ANTIDIABETIC



## NOVEL PHARMACEUTICAL

10/630877  
PCT/PTO 19 OCT 2001

This invention relates to a novel pharmaceutical, to a process for the preparation of the pharmaceutical and to the use of the pharmaceutical in medicine.

International Patent Application, Publication Number WO94/05659 discloses certain thiazolidinedione derivatives having hypoglycaemic and hypolipidaemic activity including 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (hereinafter also referred to as "Compound (I)").

International Patent Applications, Publication Numbers WO99/31093, WO99/31094 and WO99/31095 each disclose distinct hydrates of Compound (I).

It has now been discovered that Compound (I) exists in a novel polymorphic form which is particularly suitable for bulk preparation and handling. The novel form can be prepared by an efficient, economic and reproducible process particularly suited to large-scale preparation.

The novel polymorphic form ('the Polymorph') also has useful pharmaceutical properties and in particular it is indicated to be useful for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

Accordingly, the present invention provides a polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt characterised in that it:

(i) provides an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602  $\text{cm}^{-1}$ ; and/or

(ii) provides a Raman spectrum containing peaks at 1751, 1243 and 602  $\text{cm}^{-1}$ ; and/or

(iii) provides a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0 and 175.0 ppm;

and/or

(iv) provides an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms.

In one favoured aspect, the Polymorph provides an infrared spectrum substantially in accordance with Figure I.

In one favoured aspect, the Polymorph provides a Raman spectrum substantially in accordance with Figure II.

In one favoured aspect, the Polymorph provides a solid-state nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I.

In one favoured aspect, the Polymorph provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or Table II.

The present invention encompasses the Polymorph isolated in pure form or when admixed with other materials, for example the known forms of Compound I or any other material.

Thus in one aspect there is provided the Polymorph in isolated form.

In a further aspect there is provided the Polymorph in pure form.

In yet a further aspect there is provided the Polymorph in crystalline form.

The invention also provides a process for preparing the Polymorph, characterised in that a solution of Compound (I) in denatured ethanol at an elevated temperature, preferably in the range of from 65 °C to 70 °C for example 67.5 °C, is cooled preferably to a temperature in the range of from 20 °C to 25°C, so as to provide crystallisation of the Polymorph. Preferably, the solution is filtered prior to cooling. In the above-mentioned process the solution may be seeded with the Polymorph to induce crystallisation but this is not essential.

The Polymorph is then recovered from the denatured ethanol. The solution of Compound (I) in the denatured ethanol is conveniently prepared by dissolving Compound (I) in the required amount of denatured ethanol at an elevated temperature, for example 60°C or 70°C.

Conveniently the Polymorph is recovered from the denatured ethanol by filtration and subsequent drying.

In a further aspect, the invention provides a process for converting Polymorph to Compound (I), wherein a solution of Polymorph in a suitable solvent, such as acetone or ethanol, is seeded with Compound (I); preferably the reaction is carried out in an inert atmosphere, such as nitrogen. Generally, the solution of Polymorph is obtained by dissolving Polymorph at an elevated temperature in the solvent, such as acetone or ethanol.

Compound (I) is prepared according to known procedures, such as those disclosed in WO94/05659. The disclosures of WO94/05659 are incorporated herein by reference

For the avoidance of doubt the term "Compound (I)" as used herein refers to the form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt as disclosed and characterised in International Patent Application, Publication Number WO94/05659.

When used herein "denatured ethanol" means ethanol containing small amounts of methanol, usually up to 5% v/v of methanol, such as from 0.9% v/v to 5% v/v of methanol, for example ethanol containing 4%v/v of methanol.

When used herein the term 'prophylaxis of conditions associated with diabetes mellitus' includes the treatment of conditions such as insulin resistance, impaired glucose tolerance, hyperinsulinaemia and gestational diabetes.

Diabetes mellitus preferably means Type II diabetes mellitus.

5        Conditions associated with diabetes include hyperglycaemia and insulin resistance and obesity. Further conditions associated with diabetes include hypertension, cardiovascular disease, especially atherosclerosis, certain eating disorders, in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervosa, and disorders  
10       associated with over-eating, such as obesity and anorexia bulimia. Additional conditions associated with diabetes include polycystic ovarian syndrome and steroid induced insulin resistance.

15       The complications of conditions associated with diabetes mellitus encompassed herein includes renal disease, especially renal disease associated with the development of Type II diabetes including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.

20       As mentioned above the compound of the invention has useful therapeutic properties: The present invention accordingly the Polymorph for use as an active therapeutic substance.

More particularly, the present invention provides the Polymorph for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

25       The Polymorph may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier. The formulation of the Polymorph and dosages thereof are generally as disclosed for Compound (I) in International Patent Application, Publication Number WO94/05659 or WO98/55122.

30       Accordingly, the present invention also provides a pharmaceutical composition comprising the Polymorph and a pharmaceutically acceptable carrier therefor.

The Polymorph is normally administered in unit dosage form.

35       The active compound may be administered by any suitable route but usually by the oral or parenteral routes. For such use, the compound will normally be employed in the form of a pharmaceutical composition in association with a pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration.

Compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets,

capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusable solutions or suspensions, suppositories and transdermal devices. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.

Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.

Solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the active compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.

Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

Parenteral suspensions are prepared in substantially the same manner except that the active compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to  
5 facilitate uniform distribution of the active compound.

In addition such compositions may contain further active agents such as anti-hypertensive agents and diuretics.

In addition, the Polymorph may be used in combination with other antidiabetic agents such as insulin secretagogues, for example sulphonylureas, biguanides, such as metformin, alpha glucosidase inhibitors, such as acarbose, beta agonists, and insulin  
10 such as those disclosed in WO98/57649, WO98/57634, WO98/57635 or WO98/57636. The other antidiabetic agents, the amounts thereof and methods of administration are as described in the above mentioned publications. The formulation of the Polymorph and dosages thereof in said combinations are generally as disclosed  
15 for Compound (I) in the above mentioned publications. As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term  
20 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.

The present invention further provides a method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of the Polymorph to a human or  
25 non-human mammal in need thereof.

Conveniently, the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.

In the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof the Polymorph may be taken  
30 in doses, such as those described above.

Similar dosage regimens are suitable for the treatment and/or prophylaxis of non-human mammals.

In a further aspect the present invention provides the use of the Polymorph for  
35 the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

No adverse toxicological effects are indicated in the above mentioned treatments for the compounds of the invention.

The following example illustrates the invention but do not limit it in any way.

**Example 1: Preparation of the Polymorph**

A mixture of maleic acid (2.10 g) and 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione (6.0 g) were heated to 70°C in denatured ethanol (60 ml, 5%v/v methanol) until complete dissolution was obtained. The resultant solution was filtered, re-heated to 67.5°C, and then cooled to 20-25°C. The resulting crystalline product was filtered off, washed with denatured ethanol (10 ml) and dried at 50°C *in vacuo* to give the Polymorph (6.61 g, 83%).

**Example 2: Conversion of Polymorph to Compound (I)**

Polymorph (10.0 g) was added to denatured ethanol (90 ml) under nitrogen. The resulting mixture was stirred and heated to 68°C, and held at this temperature for 30 min. The solution was hot filtered to a preheated vessel (56°C) and the filter washed with hot denatured ethanol (10ml). The temperature of the filtrate was adjusted to 60°C and then cooled with stirring. At 55°C the solution was seeded with Compound (I) (0.4 g) and cooling, with stirring, continued. The resulting slurry was stirred at ambient temperature for 1 h, and the solid isolated by filtration, washed with denatured ethanol and dried at 50°C *in vacuo* to give 8.4 g (84%) Compound (I).

**Example 3: Conversion of Polymorph to Compound (I)**

Polymorph (5.0 g) was added to acetone (170 ml) and the mixture was stirred and heated to reflux temperature. After complete dissolution, the solution was heated at reflux for 30min, then filtered. The filtered solution was concentrated by distillation at atmospheric pressure (120ml of distillate was collected). The remaining solution was stirred and cooled at about 1°C/min and at 50°C seeded with Compound (I) (0.2 g). Cooling was continued at 1°C/min, and when the slurry reached 20°C stirring was continued for 1 h. The solid was isolated by filtration, washed with acetone and dried *in vacuo* at 50°C to give 4.2 g (84%) of Compound (I).

**CHARACTERISING DATA:** The following characterising data were generated for the polymorph:

**A Infrared**

The infrared absorption spectrum of a mineral oil dispersion of the Polymorph was obtained using a Nicolet 710 FT-IR spectrometer at 2 cm<sup>-1</sup> resolution. Data were digitised at 1 cm<sup>-1</sup> intervals. The spectrum obtained is shown in Figure I. Peak positions are as follows 1752, 1709, 1642, 1613, 1576, 1546, 1514, 1412, 1359,

1329, 1317, 1291, 1261, 1242, 1220, 1212, 1204, 1182, 1171, 1154, 1126, 1112, 1097, 1075, 1056, 1032, 1016, 966, 937, 918, 906, 861, 842, 821, 809, 792, 762, 743, 715, 665, 656, 650, 621, 602, 560, 541, 524 and 507  $\text{cm}^{-1}$ .

#### **B Raman**

The Raman spectrum of the Polymorph was recorded through a glass vial using a Perkin Elmer 2000R spectrometer at 4  $\text{cm}^{-1}$  resolution and is shown in Figure II (X-axis shows Intensity, Y-axis shows Raman shift  $\text{cm}^{-1}$ , 1800 - 200  $\text{cm}^{-1}$ ). Excitation was achieved using a Nd:YAG laser (1064 nm) with a power output of 400 mW. Peak positions are as follows: 1751, 1683, 1614, 1586, 1547, 1468, 1449, 1382, 1344, 1317, 1243, 1211, 1181, 1150, 1076, 1016, 991, 918, 841, 825, 773, 742, 652, 637, 619, 602, 512, 470, 428, 406, 350 and 325  $\text{cm}^{-1}$ .

#### **C NMR**

The 90.56 MHz  $^{13}\text{C}$  CP-MAS NMR spectrum for the Polymorph is shown in Figure III. Chemical shifts are tabulated in Table 1. Data were recorded at ambient temperature and 10 kHz spinning frequency on a Bruker AMX360 spectrometer, with 1.6 ms cross polarization, and a repetition time of 15 s. Chemical shifts were externally referenced to the carboxylate signal of a glycine test sample at 176.4 ppm relative to tetramethylsilane, and are regarded as accurate to within  $\pm 0.5$  ppm.

**Table I.**

$^{13}\text{C}$  Chemical Shifts of the Polymorph.

Chemical Shift (ppm)				
38.0	62.8	129.2	153.2	175.0
49.4	111.9	134.0	157.1	
51.9	114.8	138.0	170.7	
57.6	119.6	144.7	172.0	

#### **D X-Ray Powder Diffraction (XRPD)**

The XRPD pattern of the Polymorph is shown below in Figure IV and a summary of the XRPD angles and calculated lattice spacings characteristic of the Polymorph is given in Table II.



Data were acquired on a Bruker D8 Advance X-ray diffractometer with theta/theta geometry configured with a Cu anode, primary and secondary Soller slits, a secondary monochromator, and scintillation detector. The following acquisition conditions were used:

Tube anode:	Cu
Generator tension:	40 kV
Generator current:	40 mA
Start angle:	2.0 °2 $\theta$
End angle:	35.0 °2 $\theta$
Step size:	0.02 °2 $\theta$
Time per step:	2.5 s

**Table II.** X-Ray Powder Diffraction Angles and Calculated Lattice Spacings  
Characteristic of the Polymorph.

Diffraction Angle (°2θ)	Lattice Spacing (Angstroms)
9.2	9.63
11.6	7.65
12.3	7.17
13.7	6.46
14.0	6.32
14.7	6.03
14.9	5.95
15.3	5.77
16.4	5.39
18.4	4.83
18.7	4.74
19.0	4.68
19.3	4.59
20.0	4.44
21.0	4.22
21.9	4.07
22.5	3.94
23.3	3.81
24.0	3.71
24.5	3.63
24.9	3.58
25.6	3.48
26.2	3.40
27.2	3.28
27.7	3.22
28.7	3.11
29.2	3.05
29.6	3.02
30.2	2.96
30.8	2.90
31.0	2.88
31.7	2.82
32.3	2.77

32.9	2.72
33.4	2.68
34.2	2.62

## CLAIMS

1. A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the Polymorph)  
5 characterised in that it provides:
- (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602  $\text{cm}^{-1}$ ; and/or
  - (ii) a Raman spectrum containing peaks at 1751, 1243 and 602  $\text{cm}^{-1}$ ; and/or
  - (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9,  
10 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0 and 175.0 ppm;  
and/or
  - (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice  
spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms.
- 15 2. A Polymorph according to claim 1, which provides an infra red spectrum  
substantially in accordance with Figure I.
3. A Polymorph according to claim 1 or claim 2, which provides a Raman  
spectrum substantially in accordance with Figure II.
- 20 4. A Polymorph according to any one of claims 1 to 3, which provides a solid-  
state nuclear magnetic resonance spectrum substantially in accordance with Figure III  
and/or Table I.
- 25 5. A Polymorph according to any one of claims 1 to 4, which provides an X-ray  
powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or  
Table II.
6. A Polymorph according to any one of claims 1 to 5, in isolated form.
- 30 7. A Polymorph according to any one of claims 1 to 6, in pure form.
8. A Polymorph according to any one of claims 1 to 7, in crystalline form.
- 35 9. A process for preparing a Polymorph according to claim 1, characterised in  
that a solution of Compound (I) in denatured ethanol at an elevated temperature is  
cooled so as to provide crystallisation of the Polymorph after which the Polymorph is  
recovered from the denatured ethanol.

10. A pharmaceutical composition comprising an effective, non-toxic amount of a Polymorph according to claim 1 and a pharmaceutically acceptable carrier therefor.
- 5 11. A Polymorph according to claim 1, for use as an active therapeutic substance.
12. A Polymorph according to claim 1, for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.
- 10 13. The use of Polymorph for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.
- 15 14. A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Polymorph to a human or non-human mammal in need thereof.

20

ABSTRACT

A polymorphic form of 5-[4-[2-N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2,4-dione, maleic acid salt (the "Polymorph") characterized in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602  $\text{cm}^{-1}$ ; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602  $\text{cm}^{-1}$ ; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0 and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.

Figure I: Infrared Spectrum of the Polymorph.




Figure II: Raman Spectrum of the Polymorph




Figure III: Solid-State NMR Spectrum of the Polymorph



3/4

BRL-49553-C Amadeus no. 9A04582 LNB SH98905-157A1





Figure IV: X-Ray Powder Diffraction Pattern of the Polymorph



Docket No.: P32293

PCT/GB00/01522

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled;

## THIAZOLIDINEDIONE DERIVATIVE AND ITS USE AS ANTIDIABETIC

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 19 April 2000 as Serial No. PCT/GB00/01522  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

## Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9909471.6	GREAT BRITAIN	23 April 1999	Yes
9912195.6	GREAT BRITAIN	25 May 1999	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to Yuriy Stercho, GlaxoSmithKline, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5018.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Paul David James BLACKLER

Inventor's Signature: [Signature] Date: 17<sup>th</sup> November 2001

Residence: CADIZ, SPAIN ES X

Citizenship: BRITISH

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Robert Gordon GILES

Inventor's Signature: [Signature] Date: 24<sup>th</sup> October 2001


Residence: TONBRIDGE, KENT, UNITED KINGDOM

Citizenship: BRITISH CEBY

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

10030877 1042202

3. w  
Full Name of Inventor: Stephen MOORE

Inventor's Signature: 


Date: 23/10/01

Residence: TONBRIDGE, KENT, UNITED KINGDOM

Citizenship: BRITISH

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

4. w  
Full Name of Inventor: Michael John SASSE

Inventor's Signature: 

Date: 24<sup>th</sup> October 2001

Residence: TONBRIDGE, KENT, UNITED KINGDOM

Citizenship: BRITISH

Post Office Address: GlaxoSmithKline  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939